Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against Chikungunya virus in vero cells

Mohsin Khan, S R Santhosh, Mugdha Tiwari, P V Lakshmana Rao, Manmohan Parida, Mohsin Khan, S R Santhosh, Mugdha Tiwari, P V Lakshmana Rao, Manmohan Parida

Abstract

The resurgence of Chikungunya virus (CHIKV) in the form of unprecedented and explosive epidemics in India and the Indian Ocean islands after a gap of 32 years is a major public health concern. Currently, there is no specific therapy available to treat CHIKV infection. In the present study, the in vitro prophylactic and therapeutic effects of chloroquine on CHIKV replication in Vero cells were investigated. Inhibitory effects were observed when chloroquine was administered pre-infection, post-infection, and concurrent with infection, suggesting that chloroquine has prophylactic and therapeutic potential. The inhibitory effects were confirmed by performing a plaque reduction neutralization test (PRNT), real-time reverse transcriptase (RT)-PCR analysis of viral RNA levels, and cell viability assays. Chloroquine diminished CHIKV infection in a dose-dependent manner, with an effective concentration range of 5-20 microM. Concurrent addition of drug with virus, or treatment of cells prior to infection drastically reduced virus infectivity and viral genome copy number by >/=99.99%. The maximum inhibitory effect of chloroquine was observed within 1-3 hr post-infection (hpi), and treatment was ineffective once the virus successfully passed through the early stages of infection. The mechanism of inhibition of virus activity by chloroquine involved impaired endosomal-mediated virus entry during early stages of virus replication, most likely through the prevention of endocytosis and/or endosomal acidification, based on a comparative evaluation using ammonium chloride, a known lysosomotropic agent.

(c) 2010 Wiley-Liss, Inc.

References

    1. Cassell S, Edwards J, Brown DT. 1984. Effects of lysosomotropic weak bases on infection of BHK‐21 cells by Sindbis virus. J Virol 52: 857–864.
    1. Charell RN, de Lamballrie X, Raoult D. 2007. Chikungunya outbreaks‐the globalization of vector borne diseases. N Engl J Med 356: 769–771.
    1. Charmot G, Coulaud JP. 1990. Treatment of Plasmodium falciparum malaria in Africa (except cerebral malaria). MedTrop 50: 103–108.
    1. Dash PK, Parida MM, Santhosh SR, Verma SK, Tripathi NK, Ambuj S, Saxena P, Gupta N, Chaudhary M, Babu JP, Lakshmi V, Mamidi N, Subhalaxmi MV, Lakshmana Rao PV, Sekhar K. 2007. East Central South African genotype as the causative agent in reemergence of Chikungunya outbreak in India. Vector Borne Zoonotic Dis 7: 519–527.
    1. Dash PK, Tiwari M, Santhosh SR, Parida M, Lakshmana Rao PV. 2008. RNA interference mediated inhibition of Chikungunya virus replication in mammalian cells. Biochem Biophys Res Commun 376: 718–722.
    1. DeTulleo L, Kirchhausen T. 1998. The clathrin endocytic pathway in viral infection. EMBO J 17: 4585–4593.
    1. Finter NB. 1969. Dye uptake methods for assessing viral cytopathogenicity and their application to interferon assays. J Gen Virol 5: 419–427.
    1. Gilbert BE, Knight V. 1986. Biochemistry and clinical application of ribavirin. Antimicrob Agents Chemother 30: 201–205.
    1. Jupp PG, McIntosh BM. 1998. Chikungunya virus disease In: Monath TP, editor. The Arboviruses: Epidemiology and ecology. Boca Raton, FL: CRC press; pp 137–157.
    1. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. 2004. In vitro inhibition of severe acute respiratory syndrome coronavirus by Chloroquine. Biochem Biophys Res Commun 323: 264–268.
    1. Kouroumalis EA, Koskinas J. 1986. Treatment of chronic active hepatitis B (CAH B) with Chloroquine: A preliminary report. Ann Acad Med Singapore 15: 149–152.
    1. Mavalankar D, Shastri P, Raman P. 2007. Chikungunya epidemic in India: A major public‐health disaster. Lancet Infect Dis 7: 306–307.
    1. Pialoux G, Gauzere BA, Jaureguiberry S, Strobel M. 2007. Chikungunya, an epidemic arbovirosis. Lancet Infect Dis 7: 319–327.
    1. Rezza G, Nicoletti L, Angelini R, Romi R, Finarelli AC, Panning M, Cordioli P, Fortuna C, Boros S, Magurano F, Silvi G, Angelini P, Dottori M, Ciufolini MG, Majori GC, Cassone A. 2007. Infection with Chikungunya virus in Italy: An outbreak in a temperate region. Lancet 370: 1840–1846.
    1. Santhosh SR, Parida MM, Dash PK, Pateriya A, Pattnaik B, Pradhan HK, Tripathi NK, Srivastava A, Gupta N, Saxena P, Lakshmana Rao PV. 2007. Development and evaluation of SYBR Green I based one step real time RT‐PCR assay for detection and quantification of Chikungunya virus. J Clin Virol 39: 188–193.
    1. Santhosh SR, Dash PK, Parida MM, Khan M, Tiwari M, Lakshmana Rao PV. 2008. Comparative full genome analysis revealed A226V shift in 2007 Indian Chikungunya virus isolates. Virus Res 135: 36–41.
    1. Savarino A. 2005. Expanding the frontiers of existing antiviral drugs: Possible effects of HIV‐1 protease inhibitors against SARS and avian influenza. J Clin Virol 34: 170–178.
    1. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. 2003. Effects of chloroquine on viral infections: An old drug against today's diseases? Lancet Infect Dis 3: 722–727.
    1. Savarino A, Trani LD, Donatelli I, Cauda R, Cassone A. 2006. New insights into the antiviral effects of Chloroquine. Lancet Infect Dis 6: 67–69.
    1. Schuffenecker I, Iteman I, Michault A, Murri S, Frangeul L, Vaney MC, Lavenir R, Pardigon N, Reynes JM, Pettinelli F, Biscornet L, Diancourt L, Michel S, Duquerroy S, Guigon G, Frenkiel MP, Bréhin AC, Cubito N, Desprès P, Kunst F, Rey FA, Zeller H, Brisse S. 2006. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med 3: e263.
    1. Sourisseau M, Schilte C, Casartelli N, Trouillet C, Guivel‐Benhassine F, Rudnicka D, Sol‐Foulon N, Roux KL, Prevost MC, Fsihi H, Frenkiel MP, Blanchet F, Afonso PV, Ceccaldi PE, Ozden S, Gessain A, Schuffenecker I, Verhasselt B, Zamborlini A, Saïb A, Rey FA, Arenzana‐Seisdedos F, Desprès P, Michault A, Albert ML, Schwartz O. 2007. Characterization of reemerging chikungunya virus. PLoS Pathog 3: e89.
    1. Tsai WP, Nara PL, Kung HF, Oroszlan S. 1990. Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res Hum Retroviruses 6: 481–489.
    1. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST. 2005. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2: 69.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere